LOS ANGELES, CA – For decades, a diagnosis of glioblastoma, the most aggressive and common form of primary brain cancer, has been synonymous with a devastating prognosis. With an average survival time of a mere eight months, according to the National Brain Tumor Society, the medical community has grappled with a severe lack of effective treatment options. However, groundbreaking research emerging from Keck Medicine of USC offers a significant beacon of hope, suggesting a novel combination therapy could dramatically extend the lives of patients battling this formidable disease.
A new study, spearheaded by researchers at Keck Medicine of USC, has identified a powerful tripartite approach combining Tumor Treating Fields (TTFields) therapy with immunotherapy (specifically, pembrolizumab) and traditional chemotherapy (temozolomide). This innovative strategy, detailed in a recent publication, demonstrates the potential to not only prolong survival but also to fundamentally alter the immune landscape within and around glioblastoma tumors, making them vulnerable to attack in unprecedented ways.
The Dire Reality of Glioblastoma: A Formidable Foe
Glioblastoma multiforme (GBM) is a grade IV astrocytoma, characterized by its rapid growth, highly invasive nature, and resistance to conventional therapies. It originates from astrocytes, star-shaped cells that support nerve cells in the brain and spinal cord. Its insidious nature lies in its ability to infiltrate surrounding healthy brain tissue, making complete surgical removal almost impossible. Even with aggressive interventions—surgery, radiation, and chemotherapy—recurrence is almost inevitable, and the median survival rate remains tragically low.
The challenges in treating glioblastoma are multifaceted. The brain’s unique environment, protected by the formidable blood-brain barrier, restricts the passage of many therapeutic agents, including large molecule drugs like immunotherapies. Furthermore, glioblastomas are notorious for creating an immunosuppressive microenvironment, actively recruiting cells that suppress the body’s natural immune response, effectively creating a shield against potential attacks. This combination of inherent aggression, infiltrative growth, and immune evasion has rendered most standard cancer treatments, particularly immunotherapies that have revolutionized care for other cancers, largely ineffective when used in isolation for GBM.
Chronology of a Breakthrough: From Concept to Clinical Trial
The journey to this potential breakthrough is rooted in years of dedicated research, building upon existing therapies and challenging conventional wisdom.
Early Approaches and Limitations:
For many years, the standard of care for newly diagnosed glioblastoma involved maximal safe surgical resection, followed by radiation therapy. The early 2000s saw a significant advancement with the introduction of temozolomide (TMZ), an oral chemotherapy drug, which, when combined with radiation, showed a modest but statistically significant improvement in survival. This regimen became the cornerstone of glioblastoma treatment, yet its benefits remained limited, underscoring the urgent need for further innovation.
The Advent of Tumor Treating Fields (TTFields):
In 2015, the landscape of glioblastoma treatment saw another significant addition with the FDA approval of Tumor Treating Fields (TTFields) therapy, delivered via a device called Optune (manufactured by Novocure). TTFields therapy employs low-intensity, intermediate-frequency alternating electric fields that are delivered non-invasively to the tumor region through transducer arrays placed on the patient’s scalp. The fundamental principle behind TTFields is its ability to disrupt cell division (mitosis) in rapidly dividing cancer cells by physically interfering with the formation of the mitotic spindle and causing abnormal chromosome segregation. This leads to cell cycle arrest and programmed cell death.
While TTFields, in combination with temozolomide, demonstrated improved overall survival compared to temozolomide alone, it still didn’t fully address the profound challenges posed by glioblastoma’s immune evasion.
The Immunotherapy Puzzle in Glioblastoma:
Immunotherapy, particularly immune checkpoint inhibitors (ICIs) like pembrolizumab, has transformed the treatment of many advanced cancers, including melanoma and lung cancer. These drugs work by unleashing the body’s own immune system, specifically T cells, to identify and destroy cancer cells. However, in glioblastoma, immunotherapy alone has largely failed. Researchers theorized this failure stemmed from the "cold" immune environment of glioblastomas – a scarcity of tumor-infiltrating T cells and a highly immunosuppressive milieu. The blood-brain barrier further complicates the delivery of immune cells and therapeutic agents to the tumor site.
Dr. Tran’s Hypothesis: In Situ Immunization:
This is where David Tran, MD, PhD, chief of neuro-oncology with Keck Medicine, co-director of the USC Brain Tumor Center, and corresponding author of the study, entered the picture. Dr. Tran, who has been researching TTFields for over a decade, hypothesized that the electric fields, beyond their direct anti-mitotic effects, might possess an unappreciated immune-modulating capability. He theorized that TTFields could potentially act as an "in situ immunization" strategy – a way to initiate an immune reaction directly within the tumor itself, thereby overcoming the challenges of the blood-brain barrier and the immunosuppressive microenvironment. If TTFields could draw T cells into the tumor and make the tumor cells more visible to the immune system, then immune checkpoint inhibitors like pembrolizumab might finally have a meaningful target to amplify. This innovative conceptual leap laid the groundwork for the 2-THE-TOP Phase 2 clinical trial.
Supporting Data: Unpacking the Mechanism and Trial Results
The Keck Medicine of USC study provides compelling evidence for this synergistic approach, meticulously detailing how TTFields prime the immune system to make immunotherapy effective against glioblastoma.
The Science Behind the Synergy:
-
TTFields: A Multi-pronged Attack:
- Direct Anti-tumor Effect: TTFields work by delivering low-intensity, alternating electric fields at a precise frequency (typically 200 kHz for glioblastoma) directly into the tumor. These fields exert physical forces on charged macromolecules within rapidly dividing cells, particularly during mitosis. They disrupt the formation of the mitotic spindle, the cellular machinery essential for chromosome segregation, leading to mitotic arrest and ultimately, apoptotic cell death.
- Immune Priming: Crucially, the study reveals that TTFields do more than just inhibit growth. The electric fields physically push and pull key structures inside tumor cells, leading to cellular stress and immunogenic cell death. This process causes tumor cells to release "danger signals" (e.g., ATP, HMGB1) and exposes tumor-specific antigens, effectively making the tumor more "visible" to the immune system. Researchers observed that TTFields significantly attract more tumor-fighting T cells (a type of white blood cell critical for adaptive immunity) into and around the glioblastoma.
- Overcoming the Blood-Brain Barrier: While not directly permeating the blood-brain barrier, TTFields’ ability to initiate an immune response within the tumor circumvents the need for systemic immune cells to cross this formidable barrier in large numbers initially.
-
Pembrolizumab (Immunotherapy): The Amplifier:
- Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1) pathway. Cancer cells often exploit this pathway by expressing PD-L1, which binds to PD-1 on T cells, effectively "turning off" the T cell’s ability to attack. By blocking this interaction, pembrolizumab releases the brakes on T cells, allowing them to remain active and potent.
- However, for pembrolizumab to work, there need to be T cells present in the tumor microenvironment in the first place, and they need to recognize tumor antigens. This is precisely where TTFields play their pivotal role.
-
Temozolomide (Chemotherapy): The Foundation:
- Temozolomide (TMZ) is an alkylating agent that adds methyl groups to DNA, causing DNA damage that can lead to cancer cell death. It remains a cornerstone of glioblastoma treatment. Its role in this combination therapy is likely multifaceted: it continues its direct cytotoxic effects, and it may also contribute to immunogenic cell death, further exposing tumor antigens and potentially sensitizing tumor cells to immune attack.
The Synergistic Cascade:
"By using TTFields with immunotherapy, we prime the body to mount an attack on the cancer, which enables the immunotherapy to have a meaningful effect in ways that it could not before," explained Dr. Tran. He vividly illustrates this synergy: "Think of it like a team sport — immunotherapy sends players in to attack the tumor (the offense), while TTFields weaken the tumor’s ability to fight back (the defense). And just like in team sports, the best defense is a good offense." This "in situ immunization" triggered by TTFields attracts T cells, and when followed by pembrolizumab, these T cells not only stay active longer but are also replaced by even stronger, more effective tumor-fighting T cells, amplifying the anti-cancer immune response.
Phase 2 Clinical Trial: 2-THE-TOP Results:
The study analyzed data from 2-THE-TOP, a Phase 2 clinical trial that enrolled 31 newly diagnosed glioblastoma patients who had completed standard chemoradiation therapy. Of these, 26 patients received the novel combination of TTFields, temozolomide, and pembrolizumab.
- Significant Survival Advantage: Patients who received this triple combination therapy lived approximately 10 months longer than historical control groups who had used TTFields with chemotherapy alone in the past. More strikingly, the addition of immunotherapy to TTFields and chemotherapy was associated with a remarkable 70% increase in overall survival in the study cohort.
- Intriguing Finding for Unresected Tumors: Seven of the 26 patients in the combination arm had inoperable tumors due to their challenging locations – a subgroup historically associated with the worst prognosis and severely limited treatment options. Remarkably, these patients with larger, unresected tumors showed an even stronger immune response to TTFields and lived approximately 13 months longer than patients who underwent surgical removal of their tumors. This counterintuitive finding suggests that, when it comes to kick-starting the body’s immune response against cancer, having a larger tumor may paradoxically provide more targets or a greater "antigen reservoir" for the therapy to work against. "Further studies are needed to determine the optimal role of surgery in this setting, but these findings may offer hope, particularly for glioblastoma patients who do not have surgery as an option," Dr. Tran noted.
The 2-THE-TOP trial regimen involved patients receiving six to 12 monthly treatments of chemotherapy alongside TTFields for up to 24 months, with duration determined by individual response. The immunotherapy, pembrolizumab, was administered every three weeks, starting with the second dose of chemotherapy, also for up to 24 months. Patient compliance with the TTFields device, worn for approximately 18 hours a day, is crucial for efficacy.
Official Responses and Institutional Support
The findings have generated considerable enthusiasm within the neuro-oncology community, particularly at Keck Medicine of USC and the USC Brain Tumor Center, where this research was born.
Dr. David Tran, the driving force behind this study, emphasized the profound implications: "Our findings suggest that TTFields may be the key to unlocking the value of immunotherapy in treating glioblastoma." His long-standing dedication to TTFields research, coupled with his leadership at the USC Brain Tumor Center, underscores the institutional commitment to pushing the boundaries of glioblastoma treatment.
Frances Chow, MD, a neuro-oncologist with USC Norris Comprehensive Cancer Center and the principal investigator of the Keck Medicine study site, plays a vital role in translating these research findings into patient care and advancing the ongoing clinical trials. The collaborative environment at Keck School of Medicine of USC, involving experts like Dongjiang Chen, PhD, Son Le, PhD, Harshit Manektalia, Ming Li, PhD, and Adam O’Dell, along with colleagues from the University of Florida, highlights the multidisciplinary nature of this complex research.
The National Brain Tumor Society, a leading patient advocacy organization, continually underscores the critical need for breakthroughs in glioblastoma. This study directly addresses that urgent call, offering tangible progress against a disease that has long defied effective treatment.
Implications: A New Era of Hope and Future Directions
The implications of this research are far-reaching, potentially ushering in a new era of treatment for glioblastoma patients and offering a template for overcoming immune resistance in other challenging cancers.
A Paradigm Shift for Patients:
For glioblastoma patients and their families, these findings represent more than just scientific progress; they offer a tangible glimmer of hope. The potential to significantly extend survival, particularly for those with inoperable tumors who previously faced extremely limited options, is nothing short of revolutionary. This combination therapy could fundamentally change the prognosis and quality of life for individuals grappling with this devastating diagnosis.
The Crucial Phase 3 Validation:
Recognizing the immense potential, Keck Medicine of USC is actively participating in a pivotal, multicenter Phase 3 clinical trial to definitively validate the efficacy and safety of TTFields with immunotherapy and chemotherapy. Dr. Tran serves as the chair of the steering committee for this global endeavor, reflecting his leadership in the field.
This ambitious Phase 3 trial, currently active at 28 sites across the United States, Europe, and Israel, aims to enroll over 740 patients through April 2029. It will meticulously assess the treatment’s effectiveness across various patient subgroups, including those with gross total resection, partial resection, or biopsy-only tumors. This comprehensive approach will be critical in understanding how the extent of surgical tumor removal influences the immune response and the overall benefit of the combination therapy. The robust design of this large-scale trial is essential for generating the high-level evidence required for potential regulatory approval and widespread clinical adoption.
Challenges and Future Considerations:
While the promise is immense, challenges remain. Patient compliance with the TTFields device, which must be worn for approximately 18 hours a day, is a significant factor. Further research will also need to address:
- Optimal Duration and Sequencing: Determining the ideal duration and sequencing of each component of the therapy.
- Patient Stratification: Identifying biomarkers that can predict which patients are most likely to benefit from this combination.
- Cost and Accessibility: The high cost of advanced therapies like TTFields and immunotherapy raises questions about accessibility and equitable distribution.
- Long-term Side Effects: Ongoing monitoring for any long-term side effects associated with the prolonged use of this combination.
Broader Impact on Oncology:
Beyond glioblastoma, the principle of using TTFields to "prime" the tumor microenvironment and enhance the effectiveness of immunotherapy could have profound implications for other cancers that currently show resistance to immune checkpoint inhibitors. If this immune-modulating mechanism proves generalizable, TTFields could become a valuable tool in a broader oncological arsenal.
Transparency in Research:
It is important to note the funding for this study was provided by a grant from Novocure, the manufacturer of Optune, the TTFields device used. Dr. Tran has also received honoraria from Novocure for consultant work, and he, along with Dongjiang Chen, PhD, are inventors on two patent applications related to the work reported. Such disclosures are standard practice in medical research, ensuring transparency and acknowledging potential conflicts of interest, while not diminishing the scientific rigor and potential impact of the findings.
In conclusion, the research from Keck Medicine of USC represents a monumental step forward in the relentless fight against glioblastoma. By ingeniously combining existing and emerging therapies, researchers have potentially uncovered a pathway to significantly extend life for patients facing one of medicine’s most daunting diagnoses. As the Phase 3 trial unfolds, the world watches with bated breath, hoping this glimmer of hope solidifies into a new standard of care, transforming despair into durable survival.
About the Author
